article Open AccessTop 1% cited
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
British Journal of Ophthalmology · 2014 · Vol. 98(12) · pp. 1636–1641
Robert L. Avery✉(California Retina Consultants)Alessandro Castellarin(California Retina Consultants)Nathan Steinle(California Retina Consultants)Dilsher S. Dhoot(California Retina Consultants)Dante J. Pieramici(California Retina Consultants)Robert F. See(California Retina Consultants)Stephen Couvillion(California Retina Consultants)Ma'an Nasir(California Retina Consultants)Melvin Rabena(California Retina Consultants)Kha LeMaurício MaiaJennifer Visich
Abstract
NCT02118831.
Retinal Diseases and TreatmentsRetinal and Macular SurgeryRetinal and Optic ConditionsRanibizumabAfliberceptMedicineBevacizumabPharmacokineticsOphthalmologyMacular degenerationChoroidal neovascularizationPharmacologyInternal medicine
MeSH terms
BevacizumabRanibizumabAgedBiological AvailabilityEnzyme-Linked Immunosorbent AssayFemaleHalf-LifeHumansMaleProspective StudiesRecombinant Fusion ProteinsTissue DistributionVitreous BodyAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth Factor
Funding
- Regeneron Pharmaceuticals
- American Academy of Ophthalmology
- Alimera Sciences
- Santen
- Genentech
- Allergan
Citations
367
FWCI
32.18
field-weighted impact
References
31
Percentile
100%
vs. same field & year
Citations per year
References
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Ophthalmology · 2012 · 1,702 citations
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Ophthalmology · 2006 · 798 citations
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Ophthalmology · 2012 · 773 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.